Date: August 20-21, 2020

Venue: Sheraton New York Times Square Hotel, NY

Promo code: Save 10% off the current rate with code D10-999-JDS20

Or call 888-224-2480 for fastest service.

Meet and Network with The Key Influencers Shaping the Law, Policy and Proceedings of Paragraph IV Litigation

After weeks of consideration and with your safety in mind, we’ve opted to reschedule ACI’s 14th Annual Paragraph IV Disputes to August 20-21, 2020.

For the past 13 years, leading pharmaceutical patent litigators for brand name and generic drug companies gather at the Paragraph IV Disputes conference to discuss, debate, and analyze the latest trends, judicial rulings and legislative developments affecting Hatch-Waxman litigation.

As the industry prepares to address the fall out of global pharmaceutical patent losses of billions of dollars on the Hatch-Waxman landscape, the time for this conference has never been more relevant.

To learn more, visit us at

Meet the 2020 Co-Chairs

Brian Anderson
Vice President and Assistant General Counsel, IP Litigation

Pearl T. L. Siew
Senior Vice President and Head, Intellectual Property
Eagle Pharmaceuticals, Inc.

“The ACI PIV conference is the “must attend” conference for any Hatch-Waxman practitioner. No other conference provides the opportunity to hear from and network with the top in-house representatives and leading law firms representing companies on both sides of the “v.” This conference annually delivers lively discussion and debate with thought leaders on up-to-the-minute trends and hot-button issues in this specialized practice area.”

“I’m very excited about ACI PIV 2020. This conference brings together many of the top contributors in Paragraph IV litigation, from in-house and outside counsel to Patent Office, District Court, and Federal Circuit Judges. It’s an excellent opportunity to exchange ideas and shape strategies in larger groups and smaller break-out sessions.”

Mingle with the best and brightest Hatch-Waxman practitioners from:

Bristol-Myers Squibb

Fresenius Kabi USA, LLC


Akebia Therapeutics

Akorn Pharmaceuticals

Glenmark Pharmaceuticals

Gilead Sciences

Teva Pharmaceuticals



Merck & Company


Obtain insights from these outstanding in-house counsel on their expectations from their law firm partners and the methods that have worked for them in recent battles. They will also offer advice for counsel for both brand and generic drugs for litigating efficiently and cost-effectively.

Attend the conference that the “Who’s Who” of Hatch-Waxman litigators have designated as the forum which sets the standards for Paragraph IV practice. Register now and be part of the prestigious meeting of the minds.

REGISTER NOW and save an extra 10% off the conference by using code D10-999-JDS20.

*Discount is valid for new registration only and it’s not applicable for